Research indicates exploration and/or evaluation of a potential product candidate in a nonclinical laboratory setting.
Preclinical indicates that a specific product candidate in a nonclinical setting has shown functional activity that is relevant to a targeted medical need, and is undergoing toxicology testing in preparation for filing an Investigational New Drug (IND) application.
Phase 1 clinical trials are typically conducted with a small number of patients or healthy subjects to evaluate safety, determine a safe dosage range, identify side effects, and, if possible, gain early evidence of effectiveness.
Phase 2 clinical trials are conducted with a larger group of patients to evaluate effectiveness of an investigational drug for a defined patient population, and to determine common short-term side effects and risks associated with the drug.
Phase 3 clinical trials involve large scale, multi-center, comparative trials that are conducted with patients afflicted with a target disease to evaluate the overall benefit-risk relationship of the investigational drug and to provide an adequate basis for product labeling.
Intended Use:
First-line treatment for metastatic melanoma
Technology: DNA + DMRIE-DOPE
Collaborator: AnGes
Intended Use:
Prevent CMV viral reactivation and disease after transplant
Technology: DNA + Poloxamer
Intended Use:
Protect against infection, disease, and/or viral shedding
Technology: DNA + Vaxfectin®
Intended Use:
Protect against infection, disease, and/or viral shedding
Technology: DNA + Vaxfectin®
Collaborator: US Navy
Intended Use:
Prevent infection before and during pregnancy to preclude fetal transmission
Technology: DNA Vaxfectin®
Intended Use:
Prevent recurring flare-ups, reduce viral shedding and transmission
Technology: DNA + Vaxfectin®
Collaborator: Univ of Washington, Univ of Texas
Intended Use:
Induce local growth of blood vessels to restore blood flow to limbs affected by ischemia
Technology: DNA
Collaborator: AnGes
AnGes successfully completed a small Phase 3 trial in Japan and is currently preparing for a large multinational Phase 3 trial intended to support filings for marketing approval in the United States, Europe and Japan.
Intended Use:
Induce local growth of blood vessels to restore blood flow to limbs affected by ischemia
Technology: DNA
Collaborator: Sanofi-aventis
Intended Use:
Treat non-small cell lung, breast or prostate cancer, melanoma, or carcinomas of the upper GI tract, colon, kidney, or bladder
Technology: DNA
Collaborator: Merck
Intended Use:
Prevent and/or treat infection, disease, and/or viral shedding
Technology: DNA
Collaborator: Merck
Intended Use:
Protect farm-raised salmon from infection and disease when exposed to infected wild salmon
Technology: DNA
Collaborator: Aqua Health (Novartis)
Intended Use:
Adjunct treatment to increase survival time of dogs with oral melanoma
Technology: DNA
Collaborator: Merial
Intended Use:
Prevent and/or treat infection, disease, and/or viral shedding
Technology: DNA
Collaborator: NIH
Intended Use:
Prevent and/or treat infection, disease, and/or viral shedding
Technology: DNA + Vaxfectin®
Collaborator: NMRC